Post-marketing Surveillance Study With MicardisPlus® in Treatment of Morning Hypertension (Self-monitored by Patient)

Boehringer Ingelheim

Status: Completed

Conditions: Hypertension

Treatments: Drug: MicardisPlus®

Study type: Observational

Funder types: Industry

Identifiers

NCT02243566

502.513

Details and patient eligibility

About

The purpose of the study was to examine the effect of six- to eight-week treatment with MicardisPlus® on blood pressure and the effect of patient self-monitoring on blood pressure control. In addition, the post-marketing surveillance study offered the possibility to obtain information about the influence on different laboratory parameters during treatment with MicardisPlus® from an unselected patient group under office conditions

Enrollment: 2,707 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age > 18 years
• Hypertension

Exclusion criteria

• Age < 18 years

Trial design

2,707 participants in 1 patient group

Essential hypertension

Treatment:

Drug: MicardisPlus®